P&G Case 7496RC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Barry Shantz, et al. : Confirmation No.: 4950
Serial No.: 09/918,223 : Group Art Unit: 1615
Filed: July 30, 2001 : Examiner: Susan T. Tran

For: Pre-Moistened Wipe with Lotion to Improve Dispensing

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made on the attached Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [X] 37 C.F.R. §1.97(b)(1) - U.S. Direct (use when filing IDS with nonprovisional patent application, or with Request for Continued Examination (RCE); or within 3 months of filing a nonprovisional patent application)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(1), is being filed with the patent application, with a Request for Continued Examination or within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. [] 37 C.F.R. §1.97(b)(3) - (use when filing IDS more than 3 months after filing a nonprovisional patent application, but prior to receipt of first Office Action)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

3. [] 37 C.F.R. §1.97(b)(4) - (use when filing IDS prior to receipt of first Office Action after the filing of a Request for Continued Examination (RCE) under §1.114)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(b)(4). Applicants have not received a first Office Action after filing a Request For Continued Examination (RCE). Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter (or a fee transmittal form) is enclosed to facilitate charging of the fee, if necessary.

4. [] 37 C.F.R. §1.97(c) with fee payment - (use when filing IDS after receipt of first Office Action, and before receipt of Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

5.		Information	to	be	Considered	with	Continued	Prosecution
Appl	ication	(CPA) Filing	(use	who	en filing IDS	with	a Continued	Prosecution
Appl	ication	(CPA) for Desi	ign C	(ase	. This inform	ation d	isclosure state	ment is being
filed	with a C	Continued Prose	cutio	n Ap	plication (CF	A) filed	d under 37 C.F	.R. 1.53(d).
ADD	ITION	AL ITEMS TO) BE	NO'	FED BY TH	E EXA	MINER:	
		se with applicate tent literature do				on Jur	ne 30, 2003.) (Copies of the
[]		nt to 37 C.F.R.						ance of each
[]		ants also respect- -pending applic			_			nd make of
[]	A	Additional inform	matio	n is	attached.			
					Respectful	ly subn	nitted	

Date: <u>December 9, 2003</u> **Customer No. 27752**(IDS.doc) (Last Revised 10/10/03)

Ian S. Robinson Attorney for Applicant(s) Registration No. 43,348 (513) 626-3356

PTO/SB08B (08-03)

U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

COMPLETE IF KNOWN						
Application Number	09/918,223					
Confirmation Number	4950					
Filing Date	July 30, 2001					
First Named Inventor	Barry Shantz					
Group Art Unit	1615					
Examiner Name	Susan T. Tran					
Attorney Docket Number	7496RC					

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Homebest Premium Baby Wipes, on sale in the US prior to August 31, 1999.	T ²
	1	Homebest Premium Baby Wipes, on sale in the US prior to August 31, 1999.	
			<u> </u>
			<u> </u>
	 		
			
•			1
	 		†
			
			<u> </u>
	ļ		
	<u> </u>		<u> </u>
<u> </u>			-
	<u> </u>		
	<u> </u>		1
•			
			<u> </u>
	_		
EXAMINER	└ २	DATE CONSIDERED	<u> </u>
	•	DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (extince). Applicant is to the contraction of the contr

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003)